If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 8.8% in the afternoon session after the company, ...

In a blast from the past, COVID-19 vaccine developer Moderna (NASDAQ: MRNA) just made headlines in 2026. Shares jumped up ...

Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 across the United States, European Union, Canada and Australia. These filings ...

Bayer has filed patent infringement lawsuits against COVID-19 vaccine makers Pfizer, BioNTech, Moderna, and Johnson & Johnson. The company claims these firms misused mRNA technology pioneered by ...

Bayer's Monsanto has sued Pfizer, BioNTech and Moderna for allegedly misusing its messenger RNA technology in COVID vaccines.

CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

Filed in a Delaware federal court, the lawsuits claim the companies copied technology developed by Bayer's subsidiary, Monsanto, in the 1980s. This pioneering work, originally designed to strengthen ...

(The Hill) — Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover ...

(NASDAQ:MRNA) today provided an update on regulatory submissions for its investigational seasonal influenza vaccine, ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Moderna compared ...